Cerus Corporation Announces the Appointment of Alicia Goodman as New Chief Human Resources Officer
September 27 2023 - 8:30AM
Business Wire
Cerus Corporation (Nasdaq: CERS) announced today that Alicia
Goodman has been appointed to the role of Chief Human Resources
Officer (CHRO). In this role, she will focus on sustaining and
evolving the talent and organizational structure to support the
future of the business as the leader in safeguarding the global
blood supply. Ms. Goodman will also serve as a member of the
Company’s Executive Leadership Team.
“We are excited to welcome Alicia to the Cerus team,” said
William “Obi” Greenman, Cerus’ president and chief executive
officer. “As we advance on key global commercial and pipeline
initiatives, our talent, leadership and organization structure
across all levels of the organization will be critical to our
success. As a leader within the global life sciences sector, Alicia
brings a comprehensive human resources work experience that will be
immediately applicable to our current business and future product
launches.”
Ms. Goodman previously led HR at Aimmune Therapeutics for the
last four years, where she drove talent and organizational
initiatives supporting the company’s growth strategy, both before
and after Aimmune’s acquisition by Nestle Health Science. Prior to
Aimmune, she held HR leadership positions with Millendo
Therapeutics and Novartis AG, as well as head of her own HR
consultancy providing CHRO support to various start-up biotech
organizations.
“I am excited to be joining the Cerus team at this point in the
Company’s remarkable journey to improve blood safety and
availability,” said Ms. Goodman. “Cerus’ unwavering commitment to
its mission is inspiring, and I look forward to contributing to the
organization as it builds out the team and talent it needs to
maintain its leadership position in the field of transfusion
medicine.”
ABOUT CERUS
Cerus Corporation is dedicated solely to safeguarding the
world’s blood supply and aims to become the preeminent global blood
products company. Headquartered in Concord, California, the company
develops and supplies vital technologies and pathogen-protected
blood components to blood centers, hospitals, and ultimately
patients who rely on safe blood. The INTERCEPT Blood System for
platelets and plasma is available globally and remains the only
pathogen reduction system with both CE mark and FDA approval for
these two blood components. The INTERCEPT red blood cell system is
under regulatory review in Europe, and in late-stage clinical
development in the US. Also in the US, the INTERCEPT Blood System
for Cryoprecipitation is approved for the production of Pathogen
Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to
as INTERCEPT Fibrinogen Complex), a therapeutic product for the
treatment and control of bleeding, including massive hemorrhage,
associated with fibrinogen deficiency. For more information about
Cerus, visit www.cerus.com and follow us on LinkedIn.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Corporation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230927773898/en/
Jessica Hanover – Vice President, Corporate Affairs Cerus
Corporation 925-288-6137
Cerus (NASDAQ:CERS)
Historical Stock Chart
From Apr 2024 to May 2024
Cerus (NASDAQ:CERS)
Historical Stock Chart
From May 2023 to May 2024